- Conditions
- Healthy
- Interventions
- MBX 2109 (Part A), MBX 2109 (Part B), Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,823
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- CHF 4226 pMDI, Placebo
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- DeLand, Florida • Madisonville, Kentucky • Cincinnati, Ohio + 2 more
- Conditions
- Tumors
- Interventions
- NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
- Drug
- Lead sponsor
- Nina Bhardwaj
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Interventions
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Drug · Radiation
- Lead sponsor
- Ajjai Alva, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- American ginseng, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 326
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
- Conditions
- Prurigo Nodularis
- Interventions
- INCB054707, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Sacramento, California + 19 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ublituximab, Placebo, Fingolimod
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy Subjects
- Interventions
- KBP-7072, Placebo
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma
- Interventions
- Pegfilgrastim, Loratadine, Placebo, Questionnaires
- Drug · Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- SB656933, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
- Conditions
- Asthma
- Interventions
- GP MDI, BFF MDI, Placebo MDI
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Lancaster, California • Long Beach, California + 12 more
- Conditions
- Insomnia, Depressive Disorder, Major
- Interventions
- Eszopiclone, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 62 more
- Conditions
- Dyskinesias, Parkinson Disease
- Interventions
- Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C, Part 1, Placebo Group, Part 2, JM-010 combination Group A, Part 2, JM-010 combination Group B, Part 2, JM-010 component Group C, Part 2, Placebo Group
- Drug
- Lead sponsor
- Bukwang Pharmaceutical
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Miami, Florida • Detroit, Michigan
- Conditions
- Depression
- Interventions
- Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
- Conditions
- Essential Tremor
- Interventions
- SAGE-217, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 26
- States / cities
- Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more
- Conditions
- Breast Pain, Non-cyclical Mastalgia, Surgical Scar-Related Breast Pain
- Interventions
- Diclofenac, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- VX-814, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Sacramento, California • Denver, Colorado + 19 more
- Conditions
- Chronic Severe Plaque-type Psoriasis
- Interventions
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Acute Coronary Syndrome
- Interventions
- Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 107
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
- Conditions
- Ovarian Cancer, Ovarian Neoplasms
- Interventions
- Vigil, Placebo
- Biological · Other
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
- Conditions
- Insomnia
- Interventions
- E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Cincinnati, Ohio
- Conditions
- Schizophrenia
- Interventions
- Folic Acid, B12, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Grand Rapids, Michigan • Rochester, New York
- Conditions
- Hepatitis B, Chronic
- Interventions
- HepTcell, Placebo
- Biological · Drug
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Garden Grove, California • Redwood City, California • San Jose, California + 2 more